These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 12796539)

  • 21. Exposure to inhibitors of the renin-angiotensin system is a major independent risk factor for acute renal failure induced by sucrose-containing intravenous immunoglobulins: a case-control study.
    Moulis G; Sailler L; Sommet A; Lapeyre-Mestre M; Montastruc JL;
    Pharmacoepidemiol Drug Saf; 2012 Mar; 21(3):314-9. PubMed ID: 21953992
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravenous immunoglobulin administration: an evaluation of vital sign monitoring.
    Camp-Sorrell D; Wujcik D
    Oncol Nurs Forum; 1994 Apr; 21(3):531-5. PubMed ID: 8052549
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence and natural history of intravenous immunoglobulin-induced aseptic meningitis: a retrospective review at a single tertiary care center.
    Bharath V; Eckert K; Kang M; Chin-Yee IH; Hsia CC
    Transfusion; 2015 Nov; 55(11):2597-605. PubMed ID: 26095012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study.
    Léger JM; Chassande B; Musset L; Meininger V; Bouche P; Baumann N
    Brain; 2001 Jan; 124(Pt 1):145-53. PubMed ID: 11133794
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transmission of Hepatitis B Core Antibody and Galactomannan Enzyme Immunoassay Positivity via Immunoglobulin Products: A Comprehensive Analysis.
    Ramsay I; Gorton RL; Patel M; Workman S; Symes A; Haque T; Irish D; Seneviratne SL; Burns SO; Wey E; Lowe DM
    Clin Infect Dis; 2016 Jul; 63(1):57-63. PubMed ID: 27076567
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid.
    Gürcan HM; Ahmed AR
    Ann Pharmacother; 2007 Oct; 41(10):1604-10. PubMed ID: 17785614
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety of high-dose intravenous immunoglobulin in systemic autoimmune diseases.
    Tufan F; Kamali S; Erer B; Gul A; Inanc M; Ocal L; Konice M; Aral O
    Clin Rheumatol; 2007 Nov; 26(11):1913-5. PubMed ID: 17636363
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Barriers to the use of intravenous tissue plasminogen activator for in-hospital strokes.
    Bunch ME; Nunziato EC; Labovitz DL
    J Stroke Cerebrovasc Dis; 2012 Nov; 21(8):808-11. PubMed ID: 21640608
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concerns about the safety of intravenous immunoglobulin in acute ischaemic stroke.
    McCabe DJ; Sumaria S; Wilson LA
    Lupus; 2005; 14(5):409-10. PubMed ID: 15934444
    [No Abstract]   [Full Text] [Related]  

  • 30. Thromboembolic complications of intravenous immunoglobulin therapy in patients with neuropathy: a two-year study.
    Rajabally YA; Kearney DA
    J Neurol Sci; 2011 Sep; 308(1-2):124-7. PubMed ID: 21679973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lichenoid/Interface cutaneous eruptions to IVIg with the primary infusion may be related to the re-regulation of anti-idiotype network.
    Smith KJ; Dutka AL; Skelton HG
    J Cutan Med Surg; 1998 Oct; 3(2):96-101. PubMed ID: 9822784
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Slow and steady. Reducing thrombotic events in renal transplant recipients treated with IVIg for antibody-mediated rejection.
    Huang L; Kanellis J; Mulley W
    Nephrology (Carlton); 2011 Feb; 16(2):239-42. PubMed ID: 21272138
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pompholyx and eczematous reactions associated with intravenous immunoglobulin therapy.
    Gerstenblith MR; Antony AK; Junkins-Hopkins JM; Abuav R
    J Am Acad Dermatol; 2012 Feb; 66(2):312-6. PubMed ID: 21601310
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety of intravenous immunoglobulin and plasma exchange in critically ill patients.
    Clark SL; Rabinstein AA
    Neurol Res; 2015 Jul; 37(7):593-8. PubMed ID: 25751423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Headache and Nausea after Treatment with High-Dose Subcutaneous versus Intravenous Immunoglobulin.
    Markvardsen LH; Christiansen I; Andersen H; Jakobsen J
    Basic Clin Pharmacol Toxicol; 2015 Dec; 117(6):409-12. PubMed ID: 26096187
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of thromboembolic risk related to high-dose intravenous immunoglobulin treatment: a preliminary clinical study of 10 patients with autoimmune mucocutaneous blistering diseases.
    Mignogna MD; Fortuna G; Leuci S; Ruoppo E; Adamo D; Fedele S
    Clin Exp Dermatol; 2009 Mar; 34(2):145-50. PubMed ID: 19187294
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immediate adverse reactions to intravenous immunoglobulin in children: a single center experience.
    Kaba S; Keskindemirci G; Aydogmus C; Siraneci R; Erol Cipe F
    Eur Ann Allergy Clin Immunol; 2017 Jan; 49(1):11-14. PubMed ID: 28120600
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravenous immunoglobulin-associated cranial pachymeningitis.
    Marie I; Hervé F; Lahaxe L; Robaday S; Gerardin E; Levesque H
    J Intern Med; 2006 Aug; 260(2):164-7. PubMed ID: 16882281
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stroke and deep venous thrombosis complicating intravenous immunoglobulin infusions.
    Katz KA; Hivnor CM; Geist DE; Shapiro M; Ming ME; Werth VP
    Arch Dermatol; 2003 Aug; 139(8):991-3. PubMed ID: 12925384
    [No Abstract]   [Full Text] [Related]  

  • 40. Intravenous immunoglobulin: adverse effects and safe administration.
    Orbach H; Katz U; Sherer Y; Shoenfeld Y
    Clin Rev Allergy Immunol; 2005 Dec; 29(3):173-84. PubMed ID: 16391392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.